Monoclonal antibody for resisting I-group 8b type fowl adenovirus and application of monoclonal antibody

By developing monoclonal antibodies against group I 8b avian adenovirus and indirect immunofluorescence detection methods, the problem that the existing technology cannot distinguish group I 8b avian adenovirus is solved, and efficient and accurate detection and prevention are achieved, reducing the number of Economic losses of poultry farming.

CN118909957AActive Publication Date: 2024-11-08NANJING AGRICULTURAL UNIVERSITY +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202410987732.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-08
Estimated Expiration
2044-07-23

AI Technical Summary

Technical Problem

The existing detection methods cannot effectively distinguish Group I 8b avian adenovirus from other serotypes, resulting in the inability to accurately diagnose and prevent and control the virus, causing economic losses to the poultry breeding industry.

Method used

Monoclonal antibodies against group I 8b avian adenovirus were developed, and indirect immunofluorescence detection methods were established to specifically identify group I 8b avian adenovirus to avoid cross-reaction with other avian origin viruses.

Benefits of technology

It has achieved accurate detection and identification of group I 8b avian adenovirus, with high specificity and sensitivity, and is suitable for clinical testing and epidemiological investigations to help prevent and control the spread of the virus.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909957A_ABST
    Figure CN118909957A_ABST
Patent Text Reader

Abstract

The invention discloses an anti-I group 8b type fowl adenovirus monoclonal antibody and application thereof, and provides a hybridoma cell strain FAdV-8b-Hexon capable of secreting the anti-I group 8b type fowl adenovirus monoclonal antibody, and the preservation number of the hybridoma cell strain is CCTCC (China Center For Type Culture Collection) NO: C2024188. The invention also provides an anti-I group 8b type fowl adenovirus monoclonal antibody secreted by the hybridoma cell strain. The monoclonal antibody can specifically recognize I-group 8b-type avian adenovirus, and does not have cross reaction with other 11 I-group avian adenovirus serotypes, avian reovirus and other viruses. The method established by the invention has good specificity and sensitivity, and can be used for accurate detection and epidemiological investigation of the group I 8b type fowl adenovirus clinically.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of animal disease prevention and control detection, and specifically relates to an anti-group I type 8b avian adenovirus monoclonal antibody and an application thereof, especially an application in establishing an indirect immunofluorescence method for detecting group I type 8b avian adenovirus. Background Art

[0002] Fowl adenoviruses (FAdV) are members of the genus Adenovirus of the family Adenoviridae. They are non-enveloped double-stranded DNA viruses and are divided into groups I, II, and III based on their antigenic structures: Group I fowl adenovirus (FAdV-I) includes traditional fowl adenoviruses isolated from poultry such as chickens, turkeys, geese, ducks, and pigeons, which have common group antigens, and the representative strain is the chicken embryo lethal orphan virus (CELOV); Group II fowl adenovirus (FAdV-II) belongs to the genus Sialidase Adenovirus and does not have the same group antigens as Group I viruses, including related viruses such as turkey hemorrhagic enteritis; Group III fowl adenovirus (FAdV-III) belongs to the genus Thymovirus and only has the egg drop syndrome virus, which exhibits some of the same group antigens as FAdV-I.

[0003] FAdV-I is divided into 5 genotypes (FAdVA~E) and 12 serotypes (FAdV-1~8a, FAdV-8b~11) based on the viral gene sequence and serum cross-neutralization test. FAdV-I is widely distributed throughout the world, and poultry of all ages are susceptible. In addition to infecting chickens, the virus has also been found in turkeys, pigeons, budgies and mallards. Different serotypes of FAdV-I have different virulence and different pathogenicity to poultry. For example, FAdV-1 and FAdV-4 mainly cause gizzard erosion, ulcers and pericardial effusion hepatitis syndrome in poultry. Serotypes 2, 7, 8a, 8b, and 11 cause inclusion body hepatitis (IBH) symptoms worldwide.

[0004] Inclusion body hepatitis caused by FAdV-8b virus was first discovered in the United States in 1963, reported in Taiwan Province of my country in 1976, and reported in Hunan, Jiangsu and other provinces and cities of my country after 1988. After 2015, the infection rate of the disease in Shandong, Jilin, Henan, Hebei and other places gradually increased. Chickens aged 7 to 20 days can be infected with FAdV-8b, among which chickens aged 3 to 7 weeks are most susceptible. The main manifestations of diseased chicks are growth stunting, ruffled feathers, and crouching. Most of them die or gradually recover within 48 hours. The mortality rate caused by this disease is relatively low, at 10% to 30%. Typical IBH symptoms can be seen in autopsy of diseased chickens, namely, hemorrhage, brittleness, swelling and yellowing of the liver, and some have pathological changes such as mild pericardial effusion or kidney swelling and bleeding. After HE staining of the liver of IBH chickens, intranuclear inclusion bodies can be seen under an optical microscope.

[0005] The pathogenic mechanism of FAdV-8b and the cause of its prevalence in my country are not very clear. Since there is no approved vaccine clinically, the symptoms caused by it, such as decreased egg production, low feed conversion rate, and decreased immunity, have caused huge economic losses to my country's poultry farming industry. The disease can be transmitted both horizontally and vertically. If the breeder chickens are infected during the egg-laying period, the morbidity and mortality of commercial chickens can be greatly increased. Therefore, it is of great significance to develop detection substances and detection methods for FAdV-8b to meet the detection requirements of food safety, slaughtering, and testing agencies.

[0006] Preventing the spread of FAdV-8b is an important part of controlling the occurrence of inclusion body hepatitis, and strengthening quarantine is the key to preventing the spread of FAdV-8b, so sensitive and effective virus detection technology is very important. However, the current domestic detection methods and kits are mainly for group I avian adenovirus and serotype 4 avian adenovirus, such as the Agricultural Standard NY / T In the detection method of 4027-2021I group avian adenovirus, the detection methods include clinical diagnosis, PCR detection, fluorescent PCR detection, IFA identification, virus isolation and culture, etc., which cannot distinguish the specific infected serotype; Patent 202010304439.9 (2020) discloses an indirect immunofluorescence kit for detecting avian adenovirus group I, which also cannot distinguish the specific infected serotype; Patent CN116622643A discloses the preparation and application of monoclonal antibodies against serotype 4 avian adenovirus 100K protein, which is only for the diagnosis of serotype 4 avian adenovirus; Patent CN113981145A discloses a detection method and detection kit for group I avian adenovirus A, B, C, D and E. The fluorescent quantitative PCR method can distinguish different genotypes of group I but cannot distinguish serotypes; Patent CN202111061712 discloses a method for identifying group I avian adenovirus serotype 8, which can simultaneously identify FAdV-8a and FAdV-8b through the LAMP method, but cannot distinguish between these two serotypes. Currently, the only way to identify group I type 8b avian adenovirus is to amplify the Hexon gene, send it for sequencing, and then upload it to GenBank for BLAST analysis.

[0007] The present invention provides an anti-group I 8b avian adenovirus monoclonal antibody and establishes an indirect immunofluorescence detection method that can identify FAdV-8b serotype viruses, and cross-reacts with other 11 serotypes of group I avian adenoviruses and common avian-derived viruses such as avian reoviruses. The method is convenient and efficient, highly operable, and has high specificity and sensitivity. The promotion and use of the method is conducive to the clinical detection and epidemiological investigation of FAdV-8b, and provides a basis for the prevention, control and diagnosis of FAdV-8b. Summary of the invention

[0008] The present invention aims to provide an anti-group I type 8b avian adenovirus monoclonal antibody and its application.

[0009] Another object of the present invention is to provide an indirect immunofluorescence method for detecting serotype 8b of avian adenovirus group I. The present invention analyzes the Hexon gene of 12 serotype strains of FAdV-1, selects the FAdV-8b Hexon protein specific sequence for secondary structure, hydrophilicity, antigenicity, etc., selects the specific antigen epitope sequence, connects the prokaryotic expression vector, expresses and purifies the target protein, prepares immunogen immunized mice for monoclonal antibody preparation, establishes an indirect immunofluorescence detection method, and specifically detects and identifies FAdV-8b.

[0010] The purpose of the present invention can be achieved through the following technical solutions:

[0011] In the first aspect, the present invention claims protection for a hybridoma cell line FAdV-8b-Hexon that secretes anti-group I type 8b avian adenovirus monoclonal antibodies, and its deposit number is CCTCC NO: C2024188.

[0012] In a second aspect, the present invention claims protection for the anti-group I type 8b avian adenovirus monoclonal antibody secreted by the above hybridoma cell line.

[0013] In a third aspect, the present invention claims protection for the use of the above-mentioned anti-group I type 8b avian adenovirus monoclonal antibody in at least one of the following:

[0014] 1) Preparation of products for detecting avian adenovirus group I type 8b;

[0015] 2) Detection of avian adenovirus group I type 8b for non-diagnostic purposes.

[0016] In a fourth aspect, the present invention claims a product comprising the above-mentioned anti-group I type 8b avian adenovirus monoclonal antibody. Further, the product has the function of detecting group I type 8b avian adenovirus.

[0017] The product of the present invention is a kit, which comprises a monoclonal antibody against group I type 8b avian adenovirus, a FITC-labeled goat anti-mouse secondary antibody, a sample diluent (PBS) and a washing solution (PBST).

[0018] In the fifth aspect, the present invention claims protection for an indirect immunofluorescence detection method for detecting group I type 8b avian adenovirus for non-diagnostic purposes, using the above-mentioned anti-group I type 8b avian adenovirus monoclonal antibody as an antibody to detect whether the sample to be tested contains group I type 8b avian adenovirus. Further, the method is: adding anti-group I type 8b monoclonal antibody to the sample to be tested, adding FITC sheep anti-mouse secondary antibody after incubation and washing, observing under an inverted fluorescence microscope after incubation and washing, if specific green fluorescence appears in the cell, the sample is judged to be positive for group I type 8a avian adenovirus, otherwise it is negative.

[0019] The monoclonal antibody against group I type 8b avian adenovirus prepared according to the specific sequence of the hexon protein of group I type 8b avian adenovirus (as shown in SEQ ID NO.1) can specifically identify group I type 8b avian adenovirus and does not cross-react with other 11 serotypes of group I avian adenovirus and other avian-derived viruses such as EDSV and avian reovirus. Hexon protein is an important structural protein of avian adenovirus. The protein sequence variability of the L-loop region of the protein is the highest, contains specific antigenic determinants, and is the basis for virus serotyping.

[0020] The hybridoma cell line secreting anti-group I 8b avian adenovirus monoclonal antibody is named group I 8b avian adenovirus Hexon protein hybridoma cell line, referred to as FAdV-8b-Hexon. It was sent to the China Center for Type Culture Collection for preservation on June 26, 2024, and the preservation number is CCTCC NO: C2024188.

[0021] The present invention establishes an indirect immunofluorescence detection method for detecting group I type 8b avian adenovirus, and the establishment process of the detection method comprises the following steps:

[0022] (1) Preparation of Hexon protein immunogen of group I 8b avian adenovirus: The reference sequences of Hexon genes of 12 serotypes of group I avian adenovirus were analyzed, and the most variable part was selected for antigenic epitope analysis, including the secondary structure, hydrophilicity, etc. of the protein sequence. A 756 bp nucleic acid sequence was selected, and NdeⅠ and HindⅢ restriction sites were added to the 5' and 3' ends, respectively. After synthesis by Sangon Biotech (Shanghai) Co., Ltd., it was double-digested with NdeⅠ and HindⅢ together with the pET28a vector, and the vector was recovered and connected with the double-digested fragments. After sequencing and identification, it was transformed into Rosseta competent cells for induced expression and purification. The purified target protein had a concentration of not less than 1 mg / mL and a purity of not less than 90%, and was used as an immunogen for the preparation of monoclonal antibodies against group I 8b avian adenovirus.

[0023] (2) Preparation of monoclonal antibodies against avian adenovirus type I type 8b: 10 healthy Balb / c female mice aged 6 to 8 weeks and of moderate size were selected and immunized with Hexon purified protein. The protein and adjuvant were mixed in a ratio of 1:1 (v:v). After complete emulsification, the immunization dose for each mouse was 100 μg / mouse, and the immunization volume was 200 μL. After the initial immunization, three booster immunizations were performed by subcutaneous injection at multiple points on the back, with an interval of 14 days between each immunization. Blood was collected from the orbital venous plexus 2 weeks after the four immunizations according to the

[0024] (3) The antibody titer in the serum of the immunized mice was detected by the method. When the antibody titer in the serum of the mice reached the cell fusion condition, the booster immunization was performed by intraperitoneal injection. Within 3 to 5 days after the booster immunization, spleen cells were collected for cell fusion.

[0025] (3) Detection method of serum titer of immune Balb / c mice: 2 weeks after the mice were immunized four times, blood was collected from the orbital venous plexus to separate serum, and purified Hexon protein was used as the coating antigen at a coating concentration of 2 μg / mL. The cells were kept at 4°C overnight, washed 3 times with PBST, blocked with PBST containing 2% skimmed milk powder (2 g skimmed milk powder was added to 100 mL PBST buffer) for 2 h, washed 3 times with PBST, 3 min / time, discarded the washing solution, and placed at 4°C for use. The serum of immune mice was used as the positive serum for 2-fold dilution, and the serum of blank group mice was used as the negative serum. They were added to the ELISA plate, 100 μL was added to each well, incubated at 37°C for 60 min, and then washed 3 times with PBST, 3 min / time. 1:5000 diluted FITC-goat anti-mouse secondary antibody was added to each well, 100 μL / well, incubated at 37°C for 1 h, and washed 3 times with PBST, 3 min / time. Add 100 μL of colorimetric solution to each well and color for 10 minutes in the dark. After incubation, add 50 μL of stop solution to each well to terminate the reaction. Place in a microplate reader and read the OD 450 value.

[0026] (4) Fusion and screening of hybridoma cells: Balb / c mice with high serum titers were selected, killed by cervical dislocation, and then immersed in 75% alcohol for 5 minutes for disinfection. The sterilized mice were fixed, the spleen was removed, and the spleen was placed in a homogenizer and ground with basic culture medium. After standing, the supernatant was removed by centrifugation, and the cells were resuspended in an appropriate volume of HAT selection culture medium. The prepared mouse spleen cells were fused with myeloma cells SP2 / 0 using the PEG method to prepare hybridoma cells. The fused hybridoma cells were screened using HAT culture medium, and the cell growth was observed. When the hybridoma cells with good growth status were retained, the cell supernatant on the 10th to 14th day after cell fusion was taken for antibody identification. The hybridoma cell lines secreting positive antibodies were numbered, and the positive cell lines were continuously expanded and cultured using the limiting dilution method until the cell positive rate reached 100%, and the strains were preserved and frozen. Mice were immunized, ascites was prepared, and protein-A affinity purification was used to obtain monoclonal antibodies against avian adenovirus group I type 8b.

[0027] (5) Establishment of indirect immunofluorescence method for group I type 8b avian adenovirus: This detection method includes monoclonal antibody for group I type 8b avian adenovirus and commercial FITC goat anti-mouse (purchased from Sigma). The steps of this immunofluorescence detection and the positive standard are as follows: the sample to be tested is inoculated into chicken hepatoma cells (LMH) that have grown into a good monolayer, and placed in an incubator at 37°C and containing 5% CO2 for about 48 to 60 hours, the cell culture medium is discarded, and the sample is fixed with cold methanol for 15 minutes and then the methanol is discarded. The sample is opened and placed at room temperature for at least 10 minutes to allow the methanol to evaporate. After washing once with PBST, the diluted anti-group I type 8b monoclonal antibody is added, and the sample is placed at 37°C for 1 hour. After washing 3 times with PBST, the sample is gently dried. After adding 1:5000 diluted FITC goat anti-mouse secondary antibody, the sample is incubated at 37°C for 1 hour, and then washed 3 times with PBST. After gently drying, the sample is observed under an inverted fluorescence microscope. If specific green fluorescence appears in the cells, the sample is judged to be positive for group I type 8a avian adenovirus, otherwise it is negative.

[0028] The room temperature described in the present invention is 25±10° C., but is not limited thereto.

[0029] Beneficial effects of the present invention:

[0030] The present invention relates to the preparation of an anti-group I type 8b avian adenovirus monoclonal antibody and the establishment of an indirect immunofluorescence detection method for group I type 8b avian adenovirus. The anti-group I type 8b avian adenovirus monoclonal antibody of the present invention is prepared based on different serotype variant regions of the Hexon structural protein of the group I type 8b avian adenovirus, and can specifically identify the group I type 8b avian adenovirus without cross-reacting with other 11 group I avian adenovirus serotypes and viruses such as avian reovirus. The method established by the present invention has good specificity and sensitivity, and the method can be used for accurate detection of group I type 8b avian adenovirus and epidemiological investigation in clinical practice.

[0031] Collection Instructions

[0032] Culture name: Hybridoma cell line FAdV-8b-Hexon

[0033] Classification and nomenclature: Hybridoma cell line FAdV-8b-Hexon

[0034] Collection institution: China Center for Type Culture Collection

[0035] Abbreviation of depository institution: CCTCC

[0036] Address: Wuhan University, China

[0037] Deposit date: June 26, 2024

[0038] The registration number of the Collection Center is: CCTCC NO:C2024188. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 It is a protein expression diagram; M: Marker; 1: uninduced control (Rosstta); 2: precipitate after induced ultrasonic disruption of bacteria; 3: supernatant after induced ultrasonic disruption of bacteria.

[0040] Figure 2 This is the target protein purification diagram; M: Marker; 1: uninduced control; 2: supernatant after purification; 3: precipitate after purification. DETAILED DESCRIPTION

[0041] In order to make the technical problems, technical solutions and beneficial effects solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments.

[0042] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0043] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0044] Example 1: Sequence Analysis of Group I Avian Adenovirus Hexon Protein

[0045] The Hexon gene reference sequences of 12 serotypes of group I avian adenovirus were downloaded from GenBank. Protein sequence alignment analysis was performed using MegAlign software, and it was found that the Hexon protein sequences of the 12 serotypes were significantly different. DNAStar software was used to analyze the hydrophilicity, antigenicity, secondary structure and functional regions of the Hexon protein, and it was found that the 170-336aa and 430-538aa regions contained antigenic epitopes and had the most significant amino acid sequence differences, which could be used as specific test protein expression fragments. According to the results of protein structure analysis, a nucleotide fragment (756bp) that met the conditions was selected for sequence synthesis (as shown in SEQ ID NO.1), and NdeⅠ and HindⅢ restriction sites were added at the 5' and 3' ends, respectively, for double restriction digestion, connection and cloning with the expression vector. Sequence synthesis was completed at Sangon Biotech (Shanghai) Co., Ltd.

[0046] Example 2: Construction of recombinant expression plasmid and protein expression and purification

[0047] 1. Construction of recombinant expression vector

[0048] The synthesized 756bp sequence and pET28a vector were double-digested with NdeⅠ and HindⅢ restriction endonucleases, respectively. The recovered vector and double-digested fragments were connected with DNA ligase, transformed into DH5α competent strains, and 200μL of bacterial solution was spread on LB solid plates containing Amp, and inverted in a 37℃ incubator for 12-16h. Single colonies on 3 plates were picked and placed in LB liquid culture medium containing Amp, placed in a 37℃ shaker and cultured at 200r / min for 4h, and the bacterial solution was sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing. After amplification and culture of the correct strain for sequencing, the plasmid was extracted, transformed into Rosseta competent cells, and 200μL of bacterial solution was spread on LB solid plates containing Amp, and inverted in a 37℃ incubator for 12-16h. At least 3 single colonies were picked and placed in LB liquid culture medium containing Amp, and cultured in a 37°C shaker at 200 r / min for 4 h. The bacterial solution was sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing. The sequencing results were compared and analyzed, and the completely correct strain was named Pet-28a-FAdV-8b-Hexon.

[0049] 2. Inducible expression of recombinant protein

[0050] The correctly sequenced bacterial solution was inoculated into 10mL LB liquid medium containing AMP at a ratio of 1:100 (v:v), and placed in a 37℃ shaker with 200r / min vibration culture. When the OD value was 0.6-08, 1mL of the control bacterial solution was centrifuged and the supernatant was discarded for use. 0.5Mm IPTG was added to the remaining bacterial solution for induction for 3h. After the induction was completed, 1mL of the bacterial solution was centrifuged and the supernatant was discarded. Together with the control bacterial solution, the bacterial precipitate was resuspended with 200μL PBS solution, and 50μL 5× loading buffer was added respectively. The solution was heated in a 100℃ water bath for 5min, and the protein expression was detected by SDS-PAGE. The results showed that the induced bacterial solution had an obvious protein expression band at a size of about 28kDa, and the uninduced bacterial solution had no specific target band, indicating that the Hexon protein was successfully expressed.

[0051] The cultured bacterial solution was transferred to 1000mL LB liquid medium containing AMP at a ratio of 1:50, placed in a 37℃ shaker at 200r / min for shaking culture, and when the OD value was 0.6-08, 0.5mM IPTG was added for induction culture for 4h. The bacterial solution was centrifuged at 4℃, 8000r / min for 6min, the supernatant was discarded, the bacteria were resuspended with an appropriate amount of PBS, and then centrifuged at 4℃, 8000r / min for 5min, repeated twice, the culture medium components were washed, and finally the bacterial precipitate was resuspended with 100mL PBS, placed in an ice-water mixture, and the bacteria were broken with an ultrasonic disruptor for 5min, the breaking program was 40HZ, and the interval was 8s. When the bacterial suspension changed from milky white to clear and transparent, it was centrifuged at 4℃, 1000r / min for 10min, and the supernatant was placed in a new container. Take 200μL of the precipitate and supernatant respectively, add 50μL of 5× loading buffer, heat in a 100℃ water bath for 5min, and detect protein expression by SDS-PAGE. The results showed that the target protein was expressed in both the supernatant and the precipitate after induction, with the target protein mainly expressed in the precipitate. There was no specific target band in the uninduced bacterial solution ( Figure 1 ).

[0052] 3. Purification of Recombinant Protein

[0053] The results of SDS-PAGE showed that the recombinant protein was mainly expressed in the form of insoluble inclusion bodies. The Biyuntian His tag protein purification kit (denaturation-resistant formulation) was used to purify the recombinant protein in the form of inclusion bodies. Take the expressed bacterial precipitate, add the denaturing lysis solution, and ultrasonically lyse for 1 min. Centrifuge at 4°C, 12000r / min for 10 min, and collect the supernatant. Equilibrate the column twice with the denaturing lysis solution, add the lysis supernatant to the balanced column material, and shake slowly to fully bind the tag protein. Add the eluent to elute the target protein, collect the eluent in a new container, determine the concentration of the eluted protein, and collect the protein sample in the dialysis bag for refolding of the recombinant protein. The dialysis process was carried out at 4°C, and the urea concentration was reduced in sequence. Dialysis was performed for 8 hours in 6M, 4M, and 2M urea buffers, respectively, until the recombinant protein liquid became turbid, and the dialysis bag was dialyzed in PBS buffer solution. After dialysis, the recombinant protein was centrifuged at 4°C and 8000 r / min for 6 min, the supernatant was taken, the protein concentration was determined, 5× loading buffer was added, and the mixture was heated in a 100°C water bath for 5 min, and SDS-PAGE electrophoresis was performed for identification ( Figure 2 ). Using BSA as a benchmark, the purified protein concentration was no less than 1 mg / mL and the purity was no less than 90% by SDS-PAGE gel scanning analysis, and was named FAdV-8b-Hexon.

[0054] Example 3: Preparation of monoclonal antibodies

[0055] 1. Mouse Immunization

[0056] Six healthy Balb / c female mice of moderate size aged 6 to 8 weeks were selected and immunized with FAdV-8b-Hexon protein. The protein and adjuvant were mixed and emulsified at a ratio of 1:1. Each mouse was injected subcutaneously at multiple points on the back. Each mouse was immunized with 100 μg of protein and the total volume of immunization was 200 μL. The specific immunization procedure is shown below (Table 1). The immunization interval was 2 weeks. Blood was collected through the orbital venous plexus 2 weeks after the four immunizations to detect the antibody titer in the serum of the immunized mice. Mice with high serum titers were selected for booster immunization. Splenocytes were taken for cell fusion within 3 to 5 days after the booster immunization.

[0057] Table 1 Mouse immunization program

[0058]

[0059] 2. Detection of serum titer of immunized Balb / c mice

[0060] Two weeks after the mice were immunized four times, blood was collected through the orbital venous plexus to separate serum, and purified Hexon protein was used as the coating antigen, with a coating concentration of 2μg / μL, overnight at 4°C, washed 3 times with PBST, blocked with PBST containing 2% skimmed milk powder for 2h, washed 3 times with PBST, 3min / time, discarded the washing solution, and placed at 4°C for use. The immunized mouse serum was used as the positive serum for 2-fold dilution, and the blank group mouse serum was used as the negative serum, added to the ELISA plate, 100μL was added to each well, incubated at 37°C for 60min, and then washed 3 times with PBST, 3min / time. 1:5000 diluted FITC-goat anti-mouse secondary antibody was added to each well, 100μL / well, incubated at 37°C for 1h, washed 3 times with PBST, 3min / time. 100μL of color development solution was added to each well, and color was developed for 10min in the dark. After incubation, 50μL of stop solution was added to each well to terminate the reaction. Put it into the microplate reader to read the OD 490 Select mice with high serum titer for booster immunization, and take spleen cells for cell fusion 3 to 5 days after immunization.

[0061] 3. Cell fusion and screening

[0062] Resuscitate frozen SP2 / 0 myeloma cells, and when the cells grow well and adhere to the cell bottle to 80% to 90%, perform cell passage, prepare SP2 / 0 cell suspension, and inject it subcutaneously on the back of 6-week-old healthy non-immunized female Balb / c mice to proliferate the cells in vivo, and separate fresh myeloma cells. Take an immune Balb / c mouse, bleed from the orbit, collect negative serum, soak the mouse in 75% alcohol for 5 minutes for disinfection, and then take it out for the preparation of immune spleen cell suspension. Fuse immune spleen cells with SP2 / 0 cells using conventional PEG method, and place the fused cells in 96-well cell plates, and selectively culture them with HAT culture medium. The fused cells are cultured in an incubator, and after 6 days, 1 / 2 of the culture medium is replaced with HT culture medium, and the content of HAT culture medium is gradually reduced. Observe cell growth, and use indirect ELISA method to detect and screen hybridoma cells, the method is as follows:

[0063] 1) Prepare the coated plate: Coat the test plate at a protein concentration of 2 μg / mL, set up a blank control well, and coat overnight at 4°C. Wash with PBST 3 times, 3 min / time, and gently spin dry the last time. Add 200 μL of PBST containing 2% skim milk powder (PBS containing 0.05% (v / v) Tween) to each well, place at 37°C for 2 hours, and then wash with PBST (PBS containing 0.05% Tween) 3 times, 3 min / time, and gently spin dry the last time.

[0064] 2) Primary antibody incubation: Add hybridoma cell culture supernatant, negative control (SP2 / 0 culture supernatant), blank control (PBS), and positive control (FAdV-8b positive serum diluted 1000 times with PBS) as primary antibodies to the test plate, 100 μL / well, incubate at 37°C for 1 hour. Wash 3 times with PBST (PBS containing 0.05% Tween), 3 minutes / time, and gently spin dry for the last time.

[0065] 3) Secondary antibody incubation: Dilute FITC-goat anti-mouse secondary antibody 20,000 times with PBS, add 100 μL / well to the test plate, and incubate at 37°C for 1 hour. Wash with PBST (PBS containing 0.05% Tween) 3 times, 3 minutes / time, and gently shake dry for the last time.

[0066] 4) Color development: Add TMB color development solution, 100 μL / well, react at room temperature in the dark for about 10 minutes, then add 50 μL / well stop solution (1 M sulfuric acid) to stop.

[0067] 5) Reading: Place the ELISA plate into the ELISA reader and read the OD 490nm The closer the value is to 1, the stronger the positive is.

[0068] 6) Cloning: The strongly positive wells with vigorous cell growth were subjected to limiting dilution cloning three times until the cell clone antibody positivity rate reached 100%, and the hybridoma cell line FAdV-8b-Hexon with the deposit number of CCTCC NO: C2024188 was obtained.

[0069] 4. Indirect Immunofluorescence Detection

[0070] In order to verify that the prepared monoclonal antibody can specifically react with FAdV-8b, the virus liquid of 12 serotype strains of FAdV-I, avian reovirus (ARV), and egg drop syndrome virus (EDSV) (Table 2) were diluted to 100 TCID in DMEM / F12 medium. 50 / 0.1mL, inoculate 96-well cell plates with well-grown chicken hepatoma cells (LMH) monolayers, inoculate 4 wells of each strain, 100μL / well, and set up a blank control. Place in a 37°C, 5% CO2 incubator for 4 days and then perform fluorescence staining. All strains used are from the National Veterinary Microbial Bacteria (Virus) Collection Center.

[0071] Table 2 Information of strains used for testing

[0072]

[0073]

[0074] 1) Fixation: After the virus has been cultured on the cell culture plate for 4 days, discard the 96-well plate cell culture medium, add about 200 μL PBS to each well, gently wash the cell surface once, gently shake off the PBS, add 100 μL / well of -20°C pre-cooled methanol, place at room temperature for fixation for 10-15 minutes, discard the cold methanol, and dry naturally for 2-5 minutes.

[0075] 2) Primary antibody incubation: Gently wash the cell surface once with PBS, dilute the hybridoma cell line supernatant 100 times with PBS, add to the virus culture cell plate, 50 μL / well, and incubate at 37°C in the dark for 1 hour.

[0076] 3) Washing: discard the monoclonal antibody, add 0.3 mL of PBS to each well, shake gently to wash, discard the washing solution, wash 3 times with PBS, and gently spin dry for the last time.

[0077] 4) Secondary antibody incubation: Add 50 μL of FITC goat anti-mouse IgG diluted in PBS (1:200) to each well and incubate at 37°C in the dark for 1 h.

[0078] 5) Washing: discard the secondary antibody, add 0.3 mL of PBS to each well, shake gently to wash, discard the wash solution, wash 3 times with PBS, and gently spin dry for the last time.

[0079] 6) Result determination: Place the reaction plate under an inverted fluorescence microscope and observe with an excitation light of 490nm wavelength. It is found that the cells have complete cell morphology. When specific green fluorescence appears in the field of view of the inoculated well, further magnification and observation show that the nucleus and cytoplasm of the infected cells are colored, and the FAdV-8b test in this well is determined to be positive; when specific green fluorescence does not appear in the inoculated well, the field of view is dark, proving that the cells are not infected, and the FAdV-8b test in this well is determined to be negative. The results show that except for the FAdV-8b virus infection well in the well plate, which shows positive green fluorescence, the rest have no green fluorescence and are negative.

[0080] Case study 4: Identification of hybridoma cells

[0081] 1) Cultivation characteristics

[0082] The hybridoma cells were cultured in DMEM medium containing 10-15% fetal bovine serum in a 37°C, 5% CO2 incubator. The cell morphology of the hybridoma cell lines was observed under a microscope, and the cell morphology was observed to be consistent.

[0083] 2) Purity test

[0084] Sterility, mycoplasma and exogenous virus tests shall be carried out in accordance with the methods in the appendix of the current "Chinese Pharmacopoeia of Veterinary Medicine" (2020 edition), and the results should be contamination by bacteria, molds, mycoplasma and exogenous viruses.

[0085] 3) Cytokine examination

[0086] The hybridoma cells cultured for 24 hours were treated with colchicine to check the chromosome number and observe whether the chromosome characteristics were consistent with the staining characteristics of the hybridoma cells.

[0087] 4) Preparation of Ascites

[0088] Take 8-10 week old Balb / c female mice, inject 0.5 mL paraffin oil into the peritoneal cavity, and 10 days later, inject 3 million hybridoma cells diluted with serum-free DMEM basal medium into each mouse. Observe the condition of the mice every day, and when the abdomen of the mice is obviously swollen, collect the mouse ascites, centrifuge at 5000r / min for 10 minutes, and take the supernatant for aliquoting and storage.

[0089] 5) Ascites titer determination

[0090] Ascites was diluted 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800, and 1:25600 as the primary antibody and added to the fixed FAdV-8b well plate at 100 μL / well. The titer was determined according to the steps in Example 3, and the results showed that the ascites titer was 1:10000.

[0091] SEQ ID NO.1

[0092] TTCTTTAACAACTGGATCGAGGACGATGGAAACAACACAACCATCACGGGACAAATG

[0093] ACCAATCCGTACAAGAACGAGGCGCAAAACACAGCTACGGCAACAGCTGCAGCAAT

[0094] CGCCAGCGTTTCAGGCTCTTATCCTAACCCTAACGTGGGGCTGGGCATTAGCGAAATG

[0095] GGAGCCCTCACCCCGACACTAGCAGCACAGGTCGGTCTGGCCGGTCGGTTTGCCAA

[0096] GGTGTCGAATGAGAACACGCGCCTGGCTTATGGAGCGTATGTGAAGCCTCTAAAAGA

[0097] CGACGGCTCTCAGTCACTTGGAACAACGCCTTACTACGTGTTAGACACCACCGCACA

[0098] GAAATACTTGGGCGTCATGGGGGTAGAAGACTTTACGCAAAGTCTTACCTACCCAGA

[0099] CAGTCTGTTAATCCCCCCTCCTTCTGAGTACGGAGAGGTTAACAGCGGGGTGATGAA

[0100] AGCGAACAGACCCAACTACATCGGGTTCCGTGACAATTTCATCAACCTCCTGTACCAC

[0101] GATACCGGCGTGTGCTCCGGGACCCTCAACTCCGAACGGTCAGGCATGAACGTGGTG

[0102] GTGGAATTGCAGGACCGAAACACCGAACTCAGCTACCAGTACATGCTCGCCGATATG

[0103] ATGTCCAGGCATCACTATTTCGCTCTCTGGAACCAGGCCGTGGATCAGTACGACCACG

[0104] ACGTGCGCGTGTTTAACAACGACGGTTACGAGGAGGGCGTGCCCACGTACGCCTTCTCGCCCGAGGGTACA。

Claims

1. A hybridoma cell line secreting monoclonal antibodies against avian adenovirus group I type 8b, whose deposit number is CCTCC NO:C2024188.

2. A monoclonal antibody against avian adenovirus group I type 8b secreted by the hybridoma cell line of claim 1.

3. Use of the anti-group I type 8b avian adenovirus monoclonal antibody according to claim 2 in at least one of the following: 1) Preparation of products for detecting avian adenovirus group I type 8b; 2) Detection of avian adenovirus group I type 8b for non-diagnostic purposes.

4. The use according to claim 3, characterized in that: The product described is a test kit.

5. A product comprising the anti-group I type 8b avian adenovirus monoclonal antibody according to claim 2.

6. The product according to claim 5, characterized in that: The product has the function of detecting group I type 8b avian adenovirus.

7. The product according to claim 5 or 6, characterized in that: The product is a test kit.

8. The product according to claim 7, characterized in that: The kit comprises a monoclonal antibody against group I type 8b avian adenovirus, a FITC-labeled goat anti-mouse secondary antibody, a sample diluent and a washing solution.

9. An indirect immunofluorescence detection method for detecting avian adenovirus group I type 8b for non-diagnostic purposes, characterized in that: The anti-group I type 8b avian adenovirus monoclonal antibody according to claim 2 is used as an antibody to detect whether the sample to be tested contains group I type 8b avian adenovirus.

10. The method according to claim 9, characterized in that Add anti-group I type 8b monoclonal antibody to the sample to be tested, add FITC goat anti-mouse secondary antibody after incubation and washing, observe under an inverted fluorescence microscope after incubation and washing, if specific green fluorescence appears in the cells, the sample is judged to be positive for group I type 8a avian adenovirus, otherwise it is negative.

Citation Information

Patent Citations

  • Group I fowl adenovirus serotype 4 genetic engineering subunit vaccine as well as preparation method and application thereof

    CN108101967A

  • Indirect immunofluorescence kit for detecting fowl adenovirus group I

    CN111413499A

  • Monoclonal antibody for resisting group I type 4 fowl adenovirus, hybridoma cell strain of monoclonal antibody, and application of detection kit

    CN113683685A

  • 8a-type fowl adenovirus strain, inactivated vaccine as well as preparation method and application of 8a-type fowl adenovirus strain

    CN113755454A

  • Monoclonal antibody of Penton protein of FAdV-4, hybridoma cell strain secreted by monoclonal antibody and application of hybridoma cell strain

    CN116716258A